1. Svetanoff WJ, Lim-Beutal IIP, Wood RJ, Levitt MA, Rentea RM. The utilization of Botulinum toxin for Hirschsprung disease. Semin Pediatr Surg. 2022;31(2):151161. doi:10.1016/j.sempedsurg.2022.151161
2. Roorda D, Oosterlaan J, van Heurn E, Derikx J. Intrasphincteric Botulinum toxin injections for post-operative obstructive defecation problems in Hirschsprung disease: a retrospective observational study. J Pediatr Surg. 2021;56(8):1342-1348. doi:10.1016/j.jpedsurg.2020.11.025
3. Rice-Townsend SE, Nicassio L, Glazer D, et al. Characterizing the use of Botulinum toxin in patients with Hirschsprung disease treated at referral institutions for pediatric colorectal surgery. J Pediatr Surg. 2022; 57(6):1033-1039. doi:10.1016/j.jpedsurg.2022.02.005
4. Ahmad H, Rentea RM, Knaus ME, et al. Routine Botulinum toxin injection one month after a Swenson pull-through does not change the incidence of Hirschsprung associated enterocolitis. J Pediatr Surg. 2022; 57(8):1453-1457. doi:10.1016/j.jpedsurg.2021.11.029
5. Svetanoff WJ, Lopez J, Aguayo P, Hendrickson RJ, Oyetunji TA, Rentea RM. The impact of Botulinum injection for hospitalized children with Hirschsprung-associated enterocolitis. Pediatr Surg Int. 2021;37(10): 1467-1472. doi:10.1007/s00383-021-04966-3
6. Mohajerzadeh L, Zakeri AM, ZanganehKia M, Khaleghnejad Tabari A, Dara N. High dose botoxinjection for patients with internal anal sphincter achalasia persistent to posterior internal anal sphincter myectomy. Iranian J Pediatr Surg. 2020;6(2):66-73. doi:10.22037/irjps.v6i2.31946
7. Baaleman DF, Malamisura M, Benninga MA, et al. The not-so-rare absent RAIR: internal anal sphincter achalasia in a review of 1072 children with constipation undergoing high-resolution anorectal manometry. Neurogastroenterol Motil. 2021;33(4):e14028. doi:10.1111/nmo.14028